AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05025722 — intervention group
Intervention type: OTHER
Intervention: Non Interventional
Description: This is an observational study.
Study NCT05432635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myeloablative Conditioning
Description: Given standard conditioning regimen
Study NCT05808478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAC + Eye Tracking
Description: The AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.
Study NCT05808478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AAC
Description: Treatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.
Study NCT05015283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The laparoscopic One-anastomosis gastric bypass will consist of:
Description: gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
Study NCT05015283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The laparoscopic Roux-en-Y gastric bypass will consist of:
Description: the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
Study NCT04739631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: use disposable sterile needles to insert to the acupuncture point
Study NCT04739631 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: minimal acupuncture
Description: The sham-controlled group will be performed with minimal acupuncture(superficial needling) at non- acupoints.
Study NCT05676814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pecto-intercostal Fascial Block (PIFB)
Description: PIFB done with bupivacaine and epinephrine
Study NCT05676814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIFB with adjuvants
Description: PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone
Study NCT06176729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin, Rituximab, Lenalidomide
Description: polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
Study NCT04979403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
Study NCT04979403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
Study NCT06329882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
Study NCT06329882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycyclin
Description: Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
Study NCT05653115 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery
Study NCT04541394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MolecuLight
Description: MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
Study NCT05502120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with Vie-Scope laryngoscope
Description: Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications
Study NCT05502120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy with Macintosh blade laryngoscope
Description: Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
Study NCT06421194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational meal 1 - Commercial animal-based protein foods [Siew mai (6 pieces) and Ngoh hiang (2 pieces)]
Description: Participants consume a meal consisting of commercial animal-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
Study NCT06421194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational meal 2- Commercial animal-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]
Description: Participants consume a meal consisting of commercial animal-based protein foods (steamed Gyoza and oven-baked Luncheon meat) in a fasted state.
Study NCT06421194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational meal 3- Formulated plant-based protein foods [Siew mai (6 pieces) and Ngoh hiang (1 piece cut into 2)]
Description: Participants consume a meal consisting of formulated plant-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
Study NCT06421194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational meal 4- Formulated plant-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]
Description: Participants consume a meal consisting of formulated plant-based protein foods (Gyoza and Luncheon meat) in a fasted state.
Study NCT05761158 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: patients are asked to complete a questionnaire
Study NCT05158543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.
Study NCT05158543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented training (moderate intensity)
Description: In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.
Study NCT05158543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented training (high intensity)
Description: In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
Study NCT04900961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
Study NCT06254456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End expiratory occlusion test
Description: Fluid responsiveness test
Study NCT05389345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Participants will receive bilateral prefrontal anodal stimulation with cathode placed on the back of the upper neck. Transcranial direct current stimulation (tDCS) will be delivered by a research assistant under the supervision of a psychiatrist.
Study NCT05389345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive function training
Description: The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
Study NCT05389345 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Executive function training
Description: The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
Study NCT05423028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided nerve hydrodissection
Description: Peri- median nerve injection for hydrorelease and decompression
Study NCT05423028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve hydrodissection
Description: Peri- median nerve injection for hydrorelease and decompression
Study NCT04983186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensor and smartphone application
Description: Empatica E4 wearable sensor and custom-made headache smartphone application
Study NCT05858645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deucravacitinib
Description: Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
Study NCT05838014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise
Study NCT05838014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal sleep
Description: Participants will undertake \~8 hours of normal sleep prior to completing exercise
Study NCT04597424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: doxycycline
Description: 2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days.
Study NCT05793034 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biological biomarker assessment
Description: IHC, PCR, NGS, methylome
Study NCT04597424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine
Description: 1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
Study NCT04404075 — intervention group
Intervention type: OTHER
Intervention: SkinTracker Mobile App
Description: a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
Study NCT05511909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
Study NCT05511909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine
Description: Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
Study NCT05511909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
Study NCT05741047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a2Milk skim milk powder
Description: a2Milk skim milk powder (1L) containing A2 β-casein only
Study NCT05741047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yili skim milk powder
Description: Yili skim milk powder (1L) containing A1 and A2 β-caseins
Study NCT06384716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation programme based on motor control of core muscles
Description: The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.
Study NCT05954624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: oral
Study NCT05954624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: oral
Study NCT05954624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: oral
Study NCT05954624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral
Study NCT05954624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: oral
Study NCT03202147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cromolyn
Description: Active capsules for inhalation.
Study NCT03202147 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active capsules for inhalation.
Study NCT06482021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave
Description: Acetylcholine iontophoresis• The Iontophoresis comprises of electric impulses from a low voltage galvanic current stimulation unit to drive ions (Ach) (1%) into soft tissue structures.
Study NCT06212518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GENPOP ad libitum fluid intake
Description: Unrestricted fluid intake.
Study NCT06212518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GENPOP fluid restriction
Description: In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).
Study NCT06212518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATHLETE ad libitum fluid intake
Description: No restriction on fluid intake
Study NCT06212518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATHLETE restricted fluid intake
Description: Not permitted to drink during training session.
Study NCT06477471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MetProrenes
Description: Take one slow-release capsule twice a day, after meal.
Study NCT05990023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional vestibule rehabilitation training
Description: * Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~* Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~* Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~* Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~* During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements.
Study NCT05990023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task vestibule rehabilitation training
Description: * Adding a dual task of digit countdown and recitation to clinical balance training exercises.~* Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~* Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~* During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements.
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Bispecific antibody
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Immunomodulatory agent
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Immunomodulatory agent
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Monoclonal antibody
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Monoclonal antibody
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Alkylating agent (chemotherapy drug)
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Antineoplastic, Vinca Alkaloid
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Anthracycline
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Alkylating agent (chemotherapy drug)
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Corticosteroid
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigation agent 2
Description: The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
Study NCT05848765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigation agent 3
Description: The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
Study NCT06060860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules:~1. emotion awareness,~2. cognitive appraisal \& reappraisal,~3. emotion avoidance \& emotion-driven behaviors,~4. awareness and tolerance of emotion-related physical sensations, \&~5. interoceptive and situational emotion-focused exposures.~There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth.
Study NCT06060860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.